Emergent BioSolutions Inc. announced a strategic financial investment into Swiss Rockets Ltd, the parent company of Rocketvax Ltd, to support research, infrastructure development, and the expansion of Swiss Rockets’ biotechnology portfolio. This endeavor aligns with Emergent’s commitment to pioneering breakthrough medical technologies.
In addition to the investment, the companies intend to form a strategic partnership where Emergent would lead the U.S. manufacturing and commercialization efforts for four of Rocketvax’s pipeline candidates. These candidates span infectious diseases, cancer, and autoimmune disorders.
One of Rocketvax’s leading candidates is a live-attenuated nasal spray SARS-CoV-2 vaccine, which has demonstrated superior efficacy in animal studies compared to mRNA COVID-19 vaccines. This candidate has already secured a letter of intent with the U.S. National Institutes of Health (NIH) for a clinical trial under the Project NextGen initiative.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.